
The phase 2 trial assessed ABBV-154, an antibody-drug conjugate, in 181 PMR patients. ABBV-154 significantly prolonged time to flare versus placebo, with hazard ratios of 0.49 (40 mg), 0.44 (150 mg), and 0.20 (340 mg). Adverse events were similar across groups. Despite promising results, early study termination limits definitive conclusions.
Like
Save
Share